GlassScriptPhysician profile
Damon C Kimes
NPI 1134282114
$3,083.46
in general payments reported to CMS, 2019-2025
35 companies · $343 in 2025
The $343 reported for 2025 was less than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $408 · 2021: $384 · 2022: $353 · 2023: $185 · 2024: $660 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,187.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $438.50 | 2021-2025 | Levorphanol Tartrate |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $436.88 | 2019-2025 | Relistor |
| Indivior INC. | $283.52 | 2019-2025 | Sublocade |
| Uswm, LLC | $265.86 | 2021-2023 | Zimhi, Lucemyra |
| Forte Bio-Pharma LLC | $192.50 | 2019-2022 | |
| Mdd US Operations, LLC | $183.16 | 2019-2020 | |
| Medtronic, INC. | $109.15 | 2024 | Synchromedii |
| Amgen INC. | $108.88 | 2019-2022 | |
| Merz North America, INC. | $107.92 | 2019 | |
| Collegium Pharmaceutical, INC. | $100.45 | 2019-2024 | Belbuca |
| Abbott Laboratories | $80.32 | 2021-2022 | |
| Daiichi Sankyo INC. | $78.82 | 2019 | |
| Fidia Pharma USA INC. | $72.76 | 2019-2024 | Hyalgan, Triluron, Hymovis |
| Scilex Pharmaceuticals INC. | $70.26 | 2019 | |
| Sentynl Therapeutics, INC. | $69.85 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $54.20 | 2020-2021 | |
| Lilly USA, LLC | $53.44 | 2019-2020 | |
| Lundbeck LLC | $43.51 | 2021-2022 | |
| Pfizer INC. | $35.55 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $30.55 | 2019-2021 | |
| Braeburn INC. | $27.40 | 2024 | Brixadi |
| Almatica Pharma LLC | $26.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.01 | 2021 | |
| Zyla Life Sciences, INC. | $22.33 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $19.55 | 2025 | Iovera, Zilretta |
| Hikma Pharmaceuticals USA | $17.69 | 2022 | |
| Valinor Pharma, LLC | $17.61 | 2025 | Movantik |
| Astrazeneca Pharmaceuticals LP | $16.00 | 2019 | |
| Galderma Laboratories, L.P. | $15.97 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.26 | 2020 | |
| Protega Pharmaceutials INC | $13.76 | 2022 | |
| Redhill Biopharma INC. | $13.63 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.11 | 2023 | Seglentis |
| Alkermes, INC. | $12.69 | 2019 | |
| Kaleo, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Damon Kimes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.